Lupin files Spiriva in US and Enbrel in EU
Executive Summary
Lupin has realised plans to file an abbreviated new drug application (ANDA) for generic Spiriva (tiotropium bromide) in the US, as the Indian firm continues to advance its pipeline of complex generics, including respiratory drugs, and biosimilars.
You may also be interested in...
Lupin Awaits 'Clarity' On Albuterol Filing
After lower growth in its India business and impaired operations at five manufacturing units hit by US FDA action impacted Lupin's third-quarter revenues, one-offs sent its net profit crashing. While deferring reinspection timelines for its Goa and Somerset plants, the company remains confident of adding at least 15 products to its US portfolio in FY21.
Juno Looks To Shore Up Canada Supply Chains With Omega Deal
Quickfire M&A has been unveiled in Canada, with Juno Pharmaceuticals taking control of the former Nichi-Iko affiliate Omega Laboratories.
Boehringer’s Cyltezo, The Only Interchangeable Humira Biosimilar, Gets A New Form
Boehringer Ingelheim has welcomed a new FDA approval for its Cyltezo (adalimumab-adbm) interchangeable biosimilar, ahead of planned launch on 1 July.